Skip to main content
. 2019 Aug 19;4(4):e000536. doi: 10.1136/esmoopen-2019-000536

Table 1.

NGS analysis on patient samples

Sample Alteration MF (%)
Surgical specimen
KRAS G12V 21.12
TP53 Splice Site SNV 95.7
Spheroids
KRAS G12V 45.6
TP53 Splice Site SNV 97.1
Circulating tumour DNA
KRAS G12V 39.1
TP53 Splice Site SNV 17.5

MF, molecular fraction; NGS, next generation sequencing; SNV, single nucleotide variant.